Quarterly ResultJul 29, 2026, 07:10 AM
uniQure on Track for AMT-130 BLA; $259M Offering Extends Cash Runway
AI Summary
uniQure reported its second-quarter 2026 financial results, alongside significant progress in its gene therapy pipeline. The company remains on track for U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease in the third quarter of 2026, with four-year data expected in September. Financially, uniQure strengthened its position with a $259 million follow-on offering, extending its cash runway into 2030. While Q2 2026 revenue increased to $5.8 million, the net loss widened to $81.1 million. Clinical updates included early positive signals for AMT-260 in epilepsy, but AMT-191 for Fabry disease saw dosing paused due to dose-limiting toxicities.
Key Highlights
- U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease are on track for Q3 2026.
- Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026.
- Completed a $259 million follow-on offering, extending cash runway into 2030.
- Cash, cash equivalents, and current investment securities totaled $810.3 million as of June 30, 2026.
- Q2 2026 revenue was $5.8 million, an increase from $5.3 million in Q2 2025.
- Q2 2026 net loss was $81.1 million, or $1.22 per basic and diluted share.
- AMT-260 for epilepsy showed early biological signals and a favorable safety profile in Phase I/IIa.
- AMT-191 for Fabry disease showed dose-dependent α-Gal A activity, but dosing paused due to liver enzyme elevations.
Price Impact
More from QURE